Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

NCT02610075 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02610075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02610075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2015
Completion date
April 26, 2018
Enrollment
62 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumours, metastatic solid tumours, ovarian cancer